AcuraBio expands cGMP plasmid DNA CDMO services

AcuraBio, an Australian biopharmaceutical contract development and manufacturing organisation (CDMO), has announced it will provide a cGMP plasmid DNA CDMO service to the world using process platform technology from Cytiva.

According to Research and Markets, the plasmid DNA manufacturing market size is estimated to be US$525.12 million in 2022 and is expected to witness a CAGR of 13.87% from 2023 to 2033. This market growth can be attributed to a growing public understanding of cell and gene therapy, as well as the surging number of patients choosing gene therapy as their treatment of choice.

AcuraBio expects to produce more plasmid DNA for its customers around the world using Cytiva’s latest bacterial plasmid two-step purification protocol. The new protocol features single-use purification technology which is designed to deliver efficiency, high-purity level outcomes and sustainable processes.

“We are very excited to implement Cytiva’s latest technology especially because the access and production of plasmid DNA has been a bottleneck in the advanced therapy market,” said AcuraBio CEO Guillaume Herry. “We intend to bring biotechs and biopharma companies a more high-quality plasmid DNA quicker than before to help the development of new therapies such as viral vectors and mRNA.”

Jon Ince, General Manager, Commercial, Australia and New Zealand, Cytiva, added, “The adoption of Cytiva’s FlexFactory configurable manufacturing train within AcuraBio’s assets will enable AcuraBio to advance and better serve their customers based with efficient and flexible cGMP manufacturing services that address the increasing demand for high-quality therapeutics within the Australia and New Zealand region and beyond.”

Image caption: Cytiva’s ÄKTA readyflux, an automated single-use filtration system used in the two-step pDNA process.